喀什包茎手术多少钱呀喀什第二次意外怀孕,喀什泌尿外科哪家医院好,喀什市华康医院治疗附件炎多少钱,喀什较好的不要孩子医院是哪家,喀什怀孕快几天可以测出,喀什治妇科病医院哪家较好,喀什怀孕测试纸一深一浅

SAN FRANCISCO, Dec. 15 (Xinhua) -- Microsoft on Thursday announced that it will automatically upgrade the Internet Explorer (IE) to the latest version to give Windows customers more protection against malicious software.According to the company's blog post, starting from Australia and Brazil next January, users of Windows XP, Vista and Windows 7 will get the IE updates if they have turned on automatic updating via Windows Update.Microsoft said the industry has been moving toward automatic updates as a norm since the biggest online threat these days is social engineering malware typically targeting outdated software like Web browsers.Automatic upgrades, also called silent updates for displaying no messages or windows during the progress, has been deployed by Google's Chrome and Mozilla's Firefox. It can ensure users have the newest versions of the browser, and therefore is seen as a big improvement to Internet security.According to the Microsoft Security Intelligence Report released in October, 99 percent of all attacks during the first half of 2011 came from unpatched but known vulnerabilities, and 90 percent of infections were attributed to vulnerability exploitation that had a security update available from the software vendor for more than a year.In the latest research data from Web analytics company StatCounter, Microsoft's IE has a strong lead with 40.63 percent of global browser market share, followed by 25.7 percent of Chrome and 25.23 percent of Firefox.

WASHINGTON, Oct. 9 (Xinhua) -- U.S. researchers have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication Sunday in Nature Biotechnology, researchers describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage."The white blood cells known as monocytes play a critical role in the early stages of the immune response," says Matthias Nahrendorf, of the Massachusetts General Hospital (MGH) Center for Systems Biology, the paper's senior author. "We now know there are two subsets of monocytes -- an inflammatory subset that defends against pathogens and a reparative subset that supports healing. But if the inflammatory response is excessive, it can block the healing process and exacerbate conditions such as heart disease and cancer."Cells damaged by injury or disease release a cocktail of chemicals called cytokines that attract immune cells to the site of the damage. Inflammatory monocytes are guided to sites of tissue injury by a receptor protein called CCR2, and the MGH-led team devised a strategy targeting that molecule to block the inflammatory process but not the action of the reparative monocytes.Small interfering RNA (siRNA) technology prevents production of specific proteins by binding to associated messenger RNA molecules and preventing their translation. However, the technique requires extreme precision in developing the right siRNA molecule and delivering it to the correct cellular location.To make sure that their siRNA preparation targeted the right monocytes, researchers first confirmed that its use reduced levels of CCR2 in monocytes and increased levels of the fragments produced when siRNA binds to its target. They then showed that monocytes from mice treated with the siRNA preparation were unable to migrate towards CCR2's usual molecular target. Experiments in animal models of several important diseases showed that the siRNA preparation reduced the amount of cardiac muscle damaged by a heart attack, reduced the size and the number of inflammatory cells in atherosclerotic plaques and in lymphomas, and improved the survival of transplanted pancreatic islets."These inflammatory monocytes are involved in almost every major disease," Nahrendorf explains. "Anti-inflammatory drugs currently on the market hit every inflammatory cell in the body, which can produce unwanted side effects. This new siRNA treatment doesn't affect inflammatory cells that don't rely on the CCR2 receptor. That makes a big difference."

COPENHAGEN, Nov. 3 (Xinhua) -- The launch of Shenzhou-8 and the successful docking with Tiangong-1 in outer space represented a milestone in both Chinese and international space programs, Danish space scientist and media said Thursday.Michael Linden-Voernle, an astrophysicist at the Tycho Brahe Planetarium in Copenhagen, said new possibilities have opened for both Chinese and international space programs with high expectations."The recent launch of the Tiangong-1 module and now the successful docking with the Shenzhou-8 spacecraft is a very important step - a milestone for the Chinese space program in order to realize the goal of having a permanent presence in space. That means a large space station so this is really an important step, a major milestone," Linden-Voernle told Xinhua in an interview here on Thursday.Besides, a number of Danish news media reported the event, hailing it as a "historic and successful docking." The influential daily Politiken placed a two-minute's video for the successful coupling on its website and showed scenes from the Shenzhou-8 docking with Tiangong-1 together with a short commentary."Tonight two Chinese spacecraft made the historic and successful docking above the atmosphere for the first time ever. China had been the third country in the world after the United States and Russia to master the technique of docking in space. China has laid the foundation for its dominance in space," Politiken said.Jyllands-Posten, one of the bestselling newspapers in Denmark, carried a report with a brief description of China's first space docking under the headline "China closer to its own space station.""As the third country in the world, China has docked two spacecraft together perfectly in space," said Jyllands-Posten.China's unmanned spacecraft Shenzhou-8 and its space lab module Tiangong-1 rendezvoused early Thursday, successfully completing the country's first-ever space docking.

SAN FRANCISCO, Nov. 22 (Xinhua) -- Microsoft announced on Tuesday that it has acquired video search engine VideoSurf.In a press release, Microsoft said it will integrate VideoSurf' s technology across its entertainment platform to augment the Xbox 360 ecosystem and evolve search and discovery of entertainment content on Xbox LIVE.Details of the deal were not disclosed. Technology news site TechCrunch cited Israeli business newspaper Calcalist as saying that the company was bought for about 70 million U.S. dollars.The San Mateo, California-based company, founded by four Israelis in 2006, offers a technology that "sees" frames inside videos to make discovering content fast, easy and accurate.Since its founding, VideoSurf has raised 28 million dollars from several sources, including Facebook chief operating officer Sheryl Sandberg and her husband, as well as former U.S. vice president Al Gore.Last month, Microsoft announced that it will bring cable television content to its Xbox video game console over the holiday season, expanding the console into an entertainment hub.The software giant said Tuesday that the latest acquisition will make it easier for world-class video partners to take full advantage of advanced search features.

WASHINGTON, Dec. 21 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Wednesday approved Isentress for the treatment of HIV-1 infection for children and adolescents.The drug is part of a class of medications called HIV integrase strand transfer inhibitors that works by slowing the spread of HIV in the body. It was first approved for use in adult patients in October 2007, under FDA's accelerated approval program."Many young children and adolescents are living with HIV and this approval provides an important additional option for their treatment," said Edward Cox, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research.Isentress is a pill that can be taken twice daily, with or without food. The pill is also available in a chewable form. As the two tablet formulations are not interchangeable, the chewable form is only approved for use in children ages 2 to 11.A single, multi-center clinical trial of 96 children and adolescents aged 2-18 years with HIV-1 infection evaluated the safety and effectiveness of Isentress. These patients previously received treatment for HIV-1 infection. After 24 weeks of treatment with Isentress, 53 percent of these patients had an undetectable amount of HIV in their blood.According to the FDA, the most commonly reported severe, treatment-related side effects in patients taking Isentress include trouble sleeping and headache. The frequency of these side effects is similar for children and adults. One pediatric patient reported severe treatment-related insomnia, while another pediatric patient experienced a drug-related skin rash.